PDF herunterladen
Journal of Pediatric Neurology 2019; 17(04): 158-160
DOI: 10.1055/s-0038-1673637
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Levetiracetam is Less Effective than Phenobarbital in Treating Seizures Associated with KCNQ2 Variant of Benign Familial Neonatal Convulsions

Charles J. Milrod
1   Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
,
Jeremy J. Palmer
2   Touro College of Osteopathic Medicine, New York, New York, United States
,
Lewis M. Milrod
3   Departments of Pediatrics and Neurology, Hackensack Meridian School of Medicine at Seton Hall University, Jersey Shore University Medical Center, Neptune, New Jersey, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

19. Juli 2018

04. September 2018

Publikationsdatum:
13. Oktober 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Benign familial neonatal convulsions (BFNC) is an autosomal dominant disorder that presents with generalized tonic–clonic and partial seizures. Levetiracetam is becoming increasingly popular for the treatment of neonatal seizures due to a benign safety profile. Concern has arisen over possible neurotoxicity and apoptosis due to phenobarbital. A male infant with BFNC due to a KCNQ2 mutation responded to phenobarbital but not to levetiracetam. The patient's brother with the same mutation had seizures on day 4 of life; phenobarbital was administered and he became seizure free. This suggests that levetiracetam is a less effective treatment than phenobarbital for BFNC.

Keywords

KCNQ2 - neonatal - levetiracetam
 

  • References

  • 1 Zimprich F, Ronen GM, Stögmann W. , et al. Andreas Rett and benign familial neonatal convulsions revisited. Neurology 2006; 67 (05) 864-866
    CrossrefPubMedSuche in Google Scholar
  • 2 Singh NA, Charlier C, Stauffer D. , et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18 (01) 25-29
    CrossrefPubMedSuche in Google Scholar
  • 3 Cooper EC, Aldape KD, Abosch A. , et al. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. Proc Natl Acad Sci U S A 2000; 97 (09) 4914-4919
    CrossrefPubMedSuche in Google Scholar
  • 4 Yazidi GA, Shevell MI, Srour M. Two novel KCNQ2 mutations in 2 families with benign familial neonatal convulsions. Child Neurol Open 2017; 23 (04)  × 17691396
    CrossrefPubMedSuche in Google Scholar
  • 5 Aylward SC, Gilbert DL. Multigenerational benign familial neonatal seizures with inadequate clinical response to levetiracetam. J Pediatr Neurol 2011; 9 (03) 397-399
    Thieme ConnectPubMedSuche in Google Scholar
  • 6 Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol 2011; 15 (01) 1-7
    CrossrefPubMedSuche in Google Scholar
  • 7 Falsaperla R, Vitaliti G, Mauceri L. , et al. Levetiracetam in neonatal seizures as first-line treatment: a prospective study. J Pediatr Neurosci 2017; 12 (01) 24-28
    CrossrefPubMedSuche in Google Scholar
  • 8 Grinspan ZM, Shellhaas RA, Coryell J. , et al. Comparative effectiveness of levetiracetam vs phenobarbital for infantile epilepsy. JAMA Pediatr 2018; 172 (04) 352-360
    CrossrefPubMedSuche in Google Scholar
  • 9 Shellhaas RA, Wusthoff CJ, Tsuchida TN. , et al; Neonatal Seizure Registry. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology 2017; 89 (09) 893-899
    CrossrefPubMedSuche in Google Scholar
  • 10 Kato M, Yamagata T, Kubota M. , et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia 2013; 54 (07) 1282-1287
    CrossrefPubMedSuche in Google Scholar